GABA
Recent articles
Remembering GABA pioneer Edward Kravitz
The biochemist, who died last month at age 92, was part of the first neurobiology department in the world and showed that gamma-aminobutyric acid is inhibitory.
Remembering GABA pioneer Edward Kravitz
The biochemist, who died last month at age 92, was part of the first neurobiology department in the world and showed that gamma-aminobutyric acid is inhibitory.
Microglia nurture young interneurons
The immune cells secrete a growth factor that “sets the supply of GABAergic interneurons in the developing brain.”
Microglia nurture young interneurons
The immune cells secrete a growth factor that “sets the supply of GABAergic interneurons in the developing brain.”
Synaptic anomalies in autistic people support imbalance hypothesis
Increased excitatory and decreased inhibitory synapses in the prefrontal cortex of autistic people suggest broader impacts on brain function and connectivity.
Synaptic anomalies in autistic people support imbalance hypothesis
Increased excitatory and decreased inhibitory synapses in the prefrontal cortex of autistic people suggest broader impacts on brain function and connectivity.
Neurotransmitter switch-up helps fan extreme stress into full-blown fear
The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.
Neurotransmitter switch-up helps fan extreme stress into full-blown fear
The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.
Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
Trials of arbaclofen for autism yield mixed results
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
Trials of arbaclofen for autism yield mixed results
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
Cannabis compound rebalances signaling to quell seizures in mice
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
Cannabis compound rebalances signaling to quell seizures in mice
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
Single gene insufficient to account for dup15q, Angelman traits
UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.
Single gene insufficient to account for dup15q, Angelman traits
UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
Explore more from The Transmitter
Psychedelics muddy fMRI results: Q&A with Adam Bauer and Jonah Padawer-Curry
The drugs disrupt the link between vascular and neuronal activity, which complicates interpretations of fMRI data. Adopting a more holistic view of what constitutes brain activity may help, the researchers say.
Psychedelics muddy fMRI results: Q&A with Adam Bauer and Jonah Padawer-Curry
The drugs disrupt the link between vascular and neuronal activity, which complicates interpretations of fMRI data. Adopting a more holistic view of what constitutes brain activity may help, the researchers say.
First Pan-African neuroscience journal gets ready to launch
With lower-than-average article processing fees, and issues dedicated to topics important to the continent, the journal hopes to give African neuroscience research much-needed international visibility.
First Pan-African neuroscience journal gets ready to launch
With lower-than-average article processing fees, and issues dedicated to topics important to the continent, the journal hopes to give African neuroscience research much-needed international visibility.
New method identifies two-hit genetic variation in autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 October.
New method identifies two-hit genetic variation in autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 27 October.